Original Research

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

  1. Claus M. Larsen, MD1,
  2. Mirjam Faulenbach, MD2,
  3. Allan Vaag, MD, PHD1,3,
  4. Jan A. Ehses, PHD2,
  5. Marc Y. Donath, MD2 and
  6. Thomas Mandrup-Poulsen, MD, PHD1,4,5
  1. 1Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
  2. 2Clinic for Endocrinology and Diabetes, University Hospital Zurich, Zurich, Switzerland;
  3. 3University of Lund, Lund, Sweden;
  4. 4Core Unit for Medical Research Methodology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
  5. 5Karolinska Institutet, Stockholm, Sweden.
  1. Corresponding author: Thomas Mandrup-Poulsen, tmpo{at}hagedorn.dk.

  1. C.M.L., M.F., M.Y.D., and T.M.-P. contributed equally to this study.

Diabetes Care 2009 Sep; 32(9): 1663-1668. https://doi.org/10.2337/dc09-0533

Data supplements

Back to top
Diabetes Care: 32 (9)

In this Issue

September 2009, 32(9)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Add to Selected Citations

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Claus M. Larsen, Mirjam Faulenbach, Allan Vaag, Jan A. Ehses, Marc Y. Donath, Thomas Mandrup-Poulsen
Diabetes Care Sep 2009, 32 (9) 1663-1668; DOI: 10.2337/dc09-0533
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section